precursor acute lymphoblastic leukemia, although rare cases require supplementary PCR-based monitoring.
Introduction
The level of minimal residual disease (MRD) in bone marrow (BM) during early phases of treatment is the most important prognostic factor in children with acute lymphoblastic leukemia (ALL). [1] [2] [3] Consequently, MRD monitoring is applied in the treatment stratification in most ALL protocols. One strategy for MRD detection is real-time quantitative PCR (PCR-MRD) analysis of immunoglobulin (Ig)/T-cell receptor (TCR) gene rearrangements. 4, 5 Another strategy is flow cytometry-based immunophenotyping (FC-MRD), which differentiates leukemic cells from normal cells based on aberrant antigen expression (leukemia-associated immunophenotype, LAIP).
6,7
Longest clinical experience and best standardization exist for PCR-MRD, which is the method used in most treatment protocols. However, at present neither method has 100% applicability, and so it can be difficult to provide sensitive MRD results for all patients, if only a single method is used in a centre.
A critical issue of MRD studies is the occasional discordance between PCR and FC results. In rare cases, one of the two methods fails to detect MRD, while more commonly minor quantitative differences occur. Both situations can lead to different treatment stratification depending on the applied MRD method and the cut-off levels. [8] [9] [10] [11] Despite this, the identification of malignant cells by FC has only been biologically verified in one study including five patients. 12 To explore the background of such discrepancies, we investigated 53 follow-up BM samples from 28 children with B-cell precursor ALL (BCP-ALL) by flow-sorting of immunophenotype-defined residual leukemic cell populations, and subsequent analyses for leukemia-associated genomic markers by RQ-PCR and/or fluorescence in situ hybridization (FISH). Additionally, we explored to which extent cell populations scored as non-malignant contained significant amounts of leukemic cells. Flow-sorting was done on fresh BM samples during the data acquisition for standard FC- 
Design and Methods

Patient samples
We studied 53 follow-up BM samples obtained from 28 patients (diagnosed within the period June 2007 to January 2010) with childhood BCP-ALL, with exclusion of patients without an useful genomic PCR/FISH marker for the leukemic clone when screened by the standard gene rearrangement and cytogenetic panels at diagnosis (Supplementary S1). 13 Patients' cytogenetic characteristics are listed in Table 1 . The ALL diagnosis was established according to conventional criteria. 14 The patients were enrolled in the Nordic Organisation for Paediatric Haematology and Protocol-defined standard MRD follow-up BM samples were obtained at day 15 (14 samples), day 29 (17 samples) or day >29 (22 samples; six samples from day ~50, six samples from day ~79, three samples from day ~96, and seven samples from between day 106 and 213) after diagnosis.
The study was approved by the Danish Ethics Committee (HC-2008-081 and 2001-10205) , and all patients/parents gave informed consent to participate in the study.
Staining for flow cytometric immunophenotyping
BM samples were stained for flow cytometric immunophenotyping with standard procedures according to the NOPHO guidelines (Supplementary S1). 1 As part of the standard FC-based MRD monitoring, patients were analyzed at diagnosis using a broad panel of antibody-combinations for identification of leukemia-associated immunophenotypes (LAIPs). Minimum 100,000 cells were analyzed to allow the identification of heterogeneity, i.e. bimodal and broad antigen expression patterns. 13 Patients were analyzed using protocol-defined four-color (NOPHO ALL-2000) or sixcolor (NOPHO ALL-2008) MRD panels (Supplementary S1). At follow-up, patients were analyzed using the protocol-defined and additional patient-specific MRD antibody-combinations. In the following, the MRD detection performed as part of the standard clinical MRD monitoring is referred to as 'standard FC-MRD'.
Standard MRD data acquisition and simultaneous flow-sorting
Cell populations were isolated by flow-sorting on a FACSAria (BD) equipped with the FACS Diva 6 software (BD) during the data acquisition (in 'real-time') for the standard 4-6 color FC-MRD monitoring, i.e. sorting and MRD analysis were done on the same tube of cells. This set-up is useful due to the limited amount of BM material obtained at these time-points, and importantly the set-up allows for an exact verification of the MRD-FC analysis by excluding any variation related to use of different cell material and sequential cell acquisition and sorting.
Initially, a small part of the sample was acquired and sort gates were defined. LAIP sort gates were defined based on: a) the LAIP identified at diagnosis, b) the marker expression in possible previous MRD samples, and c) knowledge of the typical modulations of antigen expression of the MRD blasts during early treatment related to the actual treatment protocol used. [15] [16] [17] Expected normal Blineage cells were defined as either the normal mature B-cells (CD19pos/CD45bright), normal regenerating precursor B-cells (e.g. CD45pos/CD19pos/CD10pos), or presumed plasma cells (CD45pos/CD19dim/CD10neg/ CD20neg).
After defining the sort gates, the maximum possible number of cells was acquired and sorted (a minimum of 300,000 events and preferably 1 million or more events per antibody-combination).
When permitted by the amount of cells, a part of the sorted populations were reanalyzed, showing a sorting purity of minimum 98%. Cells for FISH and PCR analysis were flow-sorted as described previously.
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FC data analysis
Following FC data acquisition and flow-sorting, MRD was quantified according to the NOPHO guidelines (Supplementary S1). 
Detection of cytogenetic markers in flow-sorted cells by FISH
As part of the diagnostics for childhood ALL, chromosome analyses (G-banding) and FISH were performed on diagnostic BM samples of all ALL patients (Supplementary S1). 13 The cell populations flow-sorted from the follow-up BM samples were analyzed for the clone-defining FISH marker using a selected probe in each patient (Table 1) . FISH was performed according to standard procedures. For evaluation of the FISH results, all nuclei possible (maximum 50) were analyzed.
Results were expressed as percentage FISH-positive cells relative to number of cells analyzed. 
Detection of clonotypic DNA-MRD markers in flow-sorted cells by RQ-PCR
Definition of concordance between FC and PCR/FISH in individual cell populations
Results and discussion
PCR/FISH analyses in flow-sorted cell populations
In 53 
Overall evaluation of concordance
Discrepant cases
In a few cases, unexpected PCR/FISH-results in sorted cell populations were found; in two BM samples (from two patients) sorted presumed malignant cells showed discrepant PCR/FISHnegative results, and in two BM samples (from two patients) PCR-positive cells were detected among sorted presumed normal cells. These four cases were carefully reviewed in order to search for explanations and to evaluate the impact on the MRD estimate ( It must be recommended to add dyes for exclusion of dead cells in each tube.
Overall in retrospect, we found that the samples with 'discrepant' PCR/FISH-results in flow-sorted cell populations were from patients in whom the suitability of FC-MRD was questioned already at diagnosis or where the sample was of poor quality at the time of the standard MRD evaluation.
Immunophenotypic modulation of LAIP markers
We evaluated LAIP modulations in samples in which clearly detectable MRD levels (1.4E-3 to 2.1E-1) were present and in which the malignant state of the populations with modulated antigen expression was verified by flow-sorting and PCR/FISH. The LAIP modulations included CD10 down-regulation (eight out of nine patients at day 15, and six out of seven patients at day 29) and up-regulation of CD20 (five out of seven patients at day 15, and one out of three patients at day 29).
Other changes observed were down-regulation of CD34 and up-regulation of CD45 and CD22 at early time points (data not shown). These modulation patterns, here verified by flow-sorting experiments, are in line with previous studies 15, 16 and support that FC-MRD should not target only narrowly defined LAIPs but be adjusted according to the marker modulation induced by the actual treatment protocol.
Persisting bimodality
We have previously found that bimodal expression of antigen markers, most often CD34 and CD10, is common at diagnosis in BCP-ALL. 13 In this study, six patients were characterized by: a) bimodal expression of CD34 (and CD10 in one patient) at diagnosis, and b) inclusion of CD34 (or CD10 respectively) as informative marker for MRD detection, as well as c) relative high MRD levels. In seven follow-up BM samples from these patients (three day 15, three day 29 and one day 96), the leukemic state of both immunophenotype-defined subpopulations was verified by PCR/FISHpositive results in flow-sorted cells (Table 3 ). In one sample, the minor subpopulation at diagnosis became the dominating cell population at day 29, suggesting differential therapy sensitivity in CD34neg/CD34pos subpopulations, as previously observed. 22, 23 This persistence of subpopulations, at least at early follow-up time-points, indicates that FC should target all subpopulations to avoid MRD underestimation. In complex cases with bimodal expression of two (or several) markers, disease monitoring might be supplemented with PCR-MRD.
In conclusion, this study confirms that the cells identified as MRD in BCP-ALL based on their LAIP are indeed the leukemic cells harboring the clone-specific genomic markers, and that the cell populations scored as non-malignant in general do not contain significant amount of leukemic cells.
However, it is important to define up-front whether the FC-markers are fully informative at diagnosis by analyzing a higher number of cells (e.g. 100,000), and it must be recommended in the few BCP-ALL cases with non-optimal LAIPs to supplement with PCR-based MRD monitoring.
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van Dongen
Standard cytogenetic analyses
Review of Cases 1 and 2: Presumed normal cell populations with PCR/FISH-positive signals
In two BM samples from two patients, with lower standard FC-MRD values (no detectable MRD with a sensitivity of 1.0E-3 and MRD=1.4E-4, respectively), PCR-positive cells were detected in the sorted presumed normal cell populations (Table 1) .
Case 1.
One sample was a day 58 BM sample from patient #81/00 who had an only partly informative LAIP at diagnosis due to broad CD34 expression (both CD34positive and CD34negative cells) combined with low CD38 expression. Consequently, the patient was followed by both PCR-MRD and FC-MRD. The standard FC-MRD results was 1.4E-4, and the PCR-positive cells detected in presumed normal populations (isolated from three distinct antibody-combinations using sort gates:
CD19pos/CD45pos/CD22pos/CD34neg, CD19pos/CD45pos/CD10neg/CD34pos, and CD19pos/ CD45pos/CD38neg/CD34neg) correspond to possible MRD underestimation of up to 3.0E-4 (9-39%
PCR-positive cells in cell populations comprising 0.01-0.1% of the total blast count). Thus, here there might be a MRD underestimation if based on FC with only partly informative markers, illustrating the importance of primarily evaluation by PCR in such cases. This finding would not have had any clinical importance for treatment stratification in the NOPHO ALL-2008 protocol using cut-off threshold 1.0E-3. But at MRD levels close to the cut-off limit, such underestimation could be clinically important.
populations with LAIP sorted from two distinct four-color antibody-combinations. Sort gates were:
CD19pos/CD45pos/CD34neg/CD22neg, CD19pos/CD45pos/CD10neg/CD20neg and CD19pos/CD45pos/CD34pos/CD22neg, respectively. Due to the PCR-negative results, we presume that these CD19dim/CD45dim/CD20neg/CD10neg cells are normal plasma cells surviving chemotherapy, and that these could have resulted in false-positive MRD-counts by FC. However, it is possible that loss of the used clone-specific PCR marker occurred.
Case 4
The other sample was a day 29 BM sample (#76/00) with standard MRD-result of 1.1E-4. Cells with LAIP sorted were negative by FISH, shown by sequential hybridization with two different FISH probes (cep-4 (centromere, chromosome 4) probe followed by an AML-1 probe (chromosome 21)).
The used sort gate covered the CD19pos/CD34pos/CD38dim informative empty space, according to the LAIP at diagnosis. Re-inspection of the sort gate revealed presence of cells from normal neighboring cell populations but also the presence of some dead cells (events in diagonal regions), which clearly reduced the discriminatory power.
Our dead cell discrimination was guided by propidium-iodide staining in a separate tube, clearly indicating that in addition to dead granulocytes located in the low FSC/high SSC region, dead lymphoid cells and/or debris were located in the low FSC/low SSC region. Some dead cells overlap into the FSC/SSC lymphoid region and cannot be excluded without losing potential MRD events.
Consequently, the events defined in the diagonal region in fluorescence dot plots cannot be completely avoided by FSC/SSC gating
